Robert A. Figlin, MD | Authors

Articles

Selecting I-O Agents and Combinations for Patients With RCC

November 27, 2018

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.

Immunotherapy/TKI Combinations in Advanced RCC

November 08, 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.